<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03005288</url>
  </required_header>
  <id_info>
    <org_study_id>CBYM338X2211</org_study_id>
    <nct_id>NCT03005288</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes</brief_title>
  <official_title>A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety, pharmacokinetics and efficacy of bimagrumab when
      administered in overweight and obese patients with type 2 diabetes
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total body fat mass measured by DXA</measure>
    <time_frame>Week 48</time_frame>
    <description>Change from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in HbA1c.</measure>
    <time_frame>Week 24 and Week 48</time_frame>
    <description>Plasma samples are taken. A model will be used to describe HbA1c over time and the change in HbA1c at Week 24 and Week 48 will be estimated from that model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of bimagrumab: the observed minimum plasma concentration (Cmin) following drug administration</measure>
    <time_frame>Baseline, Day 84, 168, 252, 308, 336, 364, 392</time_frame>
    <description>Samples during treatment and follow up periods pre- and post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight, BMI, waist circumference, waist-to-hip ratio and lean body mass as measured by DXA</measure>
    <time_frame>Baseline, Week 24, Week 48</time_frame>
    <description>change in anthropometric body measurements and lean body mass from baseline at Week 24 and Week 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti drug antibodies after repeat doses of bimagrumab</measure>
    <time_frame>Baseline, Day 168, 336, 392</time_frame>
    <description>The immunogenic response is measured during treatment and the follow up period in obese patients with type 2 diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of bimagrumab: the observed maximum plasma concentration (Cmax) following drug administration</measure>
    <time_frame>Baseline, Day 84, 168, 252, 308. 336, 364, 392</time_frame>
    <description>Samples during treatment and follow up periods pre- and post-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body fat mass as measured by DXA</measure>
    <time_frame>Week 24</time_frame>
    <description>Change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in insulin resistance</measure>
    <time_frame>Week 24 and Week 48</time_frame>
    <description>Plasma samples are taken and insulin resistance is measured via the homeostatic model assessment using a computer to model insulin sensitivity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>bimagrumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>monthly intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>monthly intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bimagrumab</intervention_name>
    <description>monthly intravenous infusion</description>
    <arm_group_label>bimagrumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>monthly intravenous infusion</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes with HbA1c between 6.5% and 10% at screening with stable treatment for
             3 months prior to randomization

          -  On one of the following anti-diabetes regimens with stable treatment for approximately
             3 months prior to randomization: 1) metformin monotherapy; 2) DPP4 inhibitor agent
             monotherapy; 3) combination therapy of metformin and DPP4 inhibitor agent; 4) no
             anti-diabetes therapy.

          -  Body Mass Index of 28 to 40 kg/m2 at screening

          -  Body weight between 65 and 140 kg at screening

        Exclusion Criteria:

          -  Women of child-bearing potential unless they are using highly effective methods of
             contraception

          -  Diabetes other than Type 2 such as Type 1 diabetes, surgically induced diabetes,
             &quot;brittle&quot; type 2 diabetes as per investigator judgement, history of severe
             hypoglycemic episodes in the year preceding screening or hypoglycemic unawareness

          -  history of clinically significant arrythmias, heart failure, unstable angina,
             myocardial infarction or stroke, coronary artery bypass graft surgery, or percutaneous
             coronary intervention, deep vein thrombosis/pulmonary embolism, valve disorders or
             defects, pulmonary hypertension within 6 months of screening or 1 year for
             drug-eluting stents

          -  tachycardia

          -  use of anti-obesity medications, nutritional supplements or over the counter products
             for weight loss within 3 months of screening

          -  use of medications known to induce weight gain such as some anti-convulsant and
             psychotropic medications within 3 months of screening

          -  Any chronic active infection (e.g., HIV, Hepatitis B or C, tuberculosis, etc) or has
             received anti-HCV treatments within the previous 6 months.

          -  uncontrolled thyroid disease. Stable euthyroid patients on stable thyroid replacement
             therapy for at least 3 months of screening are allowed.

          -  Abnormal liver function tests such as SGOT, SGPT, alkaline phosphatase, or serum
             bilirubin, or abnormal lipase and/or amylase.

          -  Known history or presence of severe active acute or chronic liver disease (e.g.,
             cirrhosis).

          -  Uncontrolled depression

          -  Use of skeletal muscle anabolic agents in any form for 3 months prior to screening

          -  Chronic kidney disease [estimated glomerular filtration rate (GFR) &lt; 30 mL/min];
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas M. Wade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>QPS MRA LLC, Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Mid Glamorgan</state>
        <zip>CF484DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 24, 2016</study_first_submitted>
  <study_first_submitted_qc>December 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2016</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>obesity</keyword>
  <keyword>DXA</keyword>
  <keyword>MRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Antibodies, Blocking</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

